Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zafar, Zahid
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
NCT05258669: Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults	Recruiting	2/3	400	US	BBV152, Covaxin	Ocugen	COVID-19	09/23	10/23
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease	Active, not recruiting	N/A	12000	Europe, US	Low-dose CT scan	Guardant Health, Inc.	Lung Cancer	12/24	12/25
Baig, Sana
NCT05258669: Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults	Recruiting	2/3	400	US	BBV152, Covaxin	Ocugen	COVID-19	09/23	10/23